Evidence map›Paper›PMID 28500913›Full record

ArticleStem cell research2017

MYB fusions and CD markers as tools for authentication and purification of cancer stem cells from salivary adenoid cystic carcinoma.

Alex Panaccione, Yi Zhang, Molly Ryan, Christopher A Moskaluk, Karen S Anderson, Wendell G Yarbrough, Sergey V Ivanov

Open access · goldAbstract read
In one paragraph

Article in Stem cell research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018
    Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Alex PanaccioneDivision of Otolaryngology, Department of Surgery, Yale School of Medicine, New Haven, CT, United States.
Yi ZhangDivision of Otolaryngology, Department of Surgery, Yale School of Medicine, New Haven, CT, United States.
Molly RyanDepartment of Pharmacology and Molecular Biophysics and Biochemistry, Yale School of Medicine, New Haven, CT, United States. Electronic address: molly.ryan@yale.edu.
Christopher A MoskalukDepartment of Pathology, University of Virginia, Charlottesville, VA, United States. Electronic address: cam5p@virginia.edu.
Karen S AndersonDepartment of Pharmacology and Molecular Biophysics and Biochemistry, Yale School of Medicine, New Haven, CT, United States. Electronic address: karen.anderson@yale.edu.
Wendell G YarbroughDivision of Otolaryngology, Department of Surgery, Yale School of Medicine, New Haven, CT, United States; H&N Disease Center, Smilow Cancer Hospital, New Haven, CT, United States; Molecular Virology Program, Yale Cancer Center, New Haven, CT, United States; Department of Pathology, United States. Electronic address: wendell.yarbrough@yale.edu.
Sergey V IvanovDivision of Otolaryngology, Department of Surgery, Yale School of Medicine, New Haven, CT, United States. Electronic address: sergey.ivanov@yale.edu.
Yale University · USUniversity of Virginia · USYale Cancer Center · US

Funding

Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Aristotelis Tsirigos · 1985 to 2026
$83.1M
INSTITUTIONAL NATIONAL RESEARCH SERVICE AWARDT32GM007324 · NIGMS · YALE UNIVERSITY · PI BENNETT, ANTON M · 1987 to 2022
$6.2M
Molecular characterization of a human salivary gland tumor xenograft bankRC1DE020687 · NIDCR · UNIVERSITY OF VIRGINIA · PI MOSKALUK, CHRISTOPHER A. · 2009 to 2010
$1000k
Role of TrkC in Neurotropic Salivary CancersR21DE022641 · NIDCR · YALE UNIVERSITY · PI IVANOV, SERGEY V · 2013 to 2014
$458k
Validated Modeling and Culture of Salivary CancersR21DE023228 · NIDCR · YALE UNIVERSITY · PI YARBROUGH, WENDELL G · 2013 to 2014
$457k
Sandy Recovery Ventana Medical Systems Discovery XTS10OD018338 · OD · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CHIRIBOGA, LUIS A · 2014 to 2014
$123k
Understanding the consequences of oncogenic mutations on FGFR signalingF31CA216915 · NCI · YALE UNIVERSITY · PI RYAN, MOLLY · 2017 to 2018
$77k
NCI NIH HHS F31 CA216915NCI NIH HHS P30 CA016087NIDCR NIH HHS R21 DE022641NIDCR NIH HHS R21 DE023228NIDCR NIH HHS RC1 DE020687NIGMS NIH HHS T32 GM007324NIH HHS S10 OD018338
6 · The paper itself

Abstract

Cancer stem cells (CSC) are considered the major cause of aggressive tumor behavior, recurrence, metastases, and resistance to radiation, making them an attractive therapeutic target. However, isolation of CSC from tumor tissue and their characterization are challenging due to uncertainty about their molecular markers and conditions for their propagation. Adenoid cystic carcinoma (ACC), which arises predominantly in the salivary glands, is a slow-growing but relentless tumor that frequently invades nerves and metastasizes. New effective treatment approaches for ACC have not emerged over the last 40years. Previously, based on a highly conserved SOX10 gene signature that we identified in the majority of ACC tumors, we suggested the existence in ACC of SOX10+ cells with neural stem properties and corroborated this hypothesis via isolation from ACC tissue a novel population of CSC, termed ACC-CSC. These cells activated NOTCH1 signaling and co-expressed SOX10 and other ACC-intrinsic neural crest stem cell markers with CD133, a CSC cell surface marker, suggesting that ACC is driven by a previously uncharacterized population of SOX10+/CD133+ cells with neural stem cell properties. Here, we authenticated ACC identity of our primary cultures by demonstrating that most of them harbor MYB-NFIB fusions, which are found in 86% of ACC. We demonstrated using CyTOF, a novel mass cytometry technology, that these cells express high β-catenin and STAT3 levels and are marked by CD24 and CD44. Finally, to streamline development of ACC cell lines, we developed RT-PCR tests for distinguishing mouse and human cells and used immunomagnetic cell sorting to eliminate mouse cells from long-term cell cultures. Overall, this study describes a new population of CSC that activates signaling pathways associated with poor prognosis, validates their ACC identity, and optimizes approaches that can be used for purification of ACC-CSC and generation of cell lines.

Indexed as

3T3 CellsAnimalsAntigens, CDBase Sequencebeta CateninBiomarkers, TumorCarcinoma, Adenoid CysticCell Line, TumorCell SeparationHumansMagneticsMiceMice, NudeNeoplastic Stem CellsOncogene Proteins, FusionProto-Oncogene Proteins c-mybAntigens, CDbeta CateninBiomarkers, TumorOncogene Proteins, FusionProto-Oncogene Proteins c-mybSTAT3 Transcription Factor

Identifiers

PMID28500913
PMCPMC5518784
OpenAlexW2610164240

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.